SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q3 Interim Management Statement

7 Nov 2014 07:00

RNS Number : 4101W
Rentokil Initial PLC
07 November 2014
 



 

 

RENTOKIL INITIAL PLC (RTO)

INTERIM MANAGEMENT STATEMENT

7 November 2014

 

 (£m)

Q3 2014

Growth

YTD 2014

Growth

AER

AER

CER

AER

AER

CER

Revenue

439.5

(3.4%)

3.3%

1,293.9

(4.1%)

2.1%

Revenue - ongoing operations1

439.5

(2.9%)

3.8%

1,293.0

(3.2%)

3.1%

Adjusted operating profit2

62.6

(4.1%)

4.0%

162.8

(1.9%)

6.2%

Adjusted profit before tax2

53.5

5.7%

15.4%

131.0

3.6%

14.1%

Profit before tax

48.8

16.7%

27.0%

115.6

28.4%

42.0%

 

Revenue (at CER)Overall, revenue from ongoing operations increased by 3.8% in Q3 in line with Q2. Revenue grew organically by 1.1% and by 2.7% from businesses acquired in the last 12 months. Growth in Q3 in the Emerging (22.4%) and Growth (6.1%) quadrants was strong, partially offset by slight declines in the Protect and Enhance (-0.1%) and Manage for Value (-0.8%) quadrants. Divestments in the Manage for Value quadrant of our Belgian Flat Linen business and our Korean JV in 2013, and our Spanish Medical business in H1 2014, reduced revenue growth by 0.5% in Q3, resulting in total revenue growth in the quarter of 3.3%.

Profit (at CER)Adjusted operating profit increased by 4.0% in Q3, reflecting growth in North America, Pacific and Germany, as well as lower overheads, partly offset by lower profits in Benelux and slower growth in France.

Adjusted profit before tax at actual exchange rates continues to be negatively impacted by the continued strengthening of Sterling. Based on current exchange rates the impact of currency movements would be around £17m for the full year, in line with our previous guidance.

Reorganisation costs and one-off items for continuing operations were significantly lower in Q3 at £0.1m versus £5.5m last year, contributing to an increase in profit before tax of 27.0% in the quarter. After taking into account currency movements, profit before tax at AER increased by 16.7%. We now expect reorganisation costs and one-off items to be less than £10m for the year.

Cash flow and interest costsOperating and free cash flow continue to be strong and we remain on track to achieve our targets for the year. During the quarter we took advantage of an invoice factoring exercise in our French business which is anticipated to increase working capital inflows by approximately £15m. With our improved net debt position we now expect interest costs to be in the region of £47m (at CER) for the year compared to the previous guidance of £50m.

M&AWe acquired 5 businesses in the quarter and have now acquired 18 businesses in pest control in the year along with one small acquisition in hygiene and three in plants. Combined annual revenues of the above businesses totalled £40m in the 12 months immediately prior to acquisition.

Commenting on the Q3 results Andy Ransom, CEO of Rentokil Initial plc, said:

"I am pleased to report that the business maintained the recent level of revenue growth in the quarter with the Pest Control category continuing to perform well in our Emerging and Growth quadrants. Challenging trading conditions persist in our European businesses, impacting our hygiene and workwear categories in our Protect & Enhance and Manage for Value quadrants.

"Profit growth in the quarter continues to reflect the benefit of more efficient businesses and reduced overheads and has been achieved despite the challenging European trading conditions. We continue to execute our strategy at pace, to drive improved revenue, profit and cash, and we expect Q4 operating performance to be in line with Q3."

 

 

Enquiries:

 

Investors / Analysts: Guy Smith Rentokil Initial plc 01276 536585/07879 662664

 

Media: Malcolm Padley Rentokil Initial plc 07788 978 199

Justine McIllroy Brunswick Group 020 7404 5959

Nina Coad

Oliver Hughes

 

A call for investors and analysts will be held on Friday 7 November at 9.15am:

 

Participant Details:

 

London, UK: +44(0)203 427 1912

Paris, France: +33(0)1 76 77 22 20

Hong Kong: +852 3002 1615

New York, USA: +1 646 254 3362

Participant PIN code: 7321731#

 

Playback Details (available for 14 days):

 

London, UK: +44(0)203 427 0598

Paris, France: +33(0)1 74 20 28 00

Hong Kong: +852 3011 4669

New York, USA: +1 347 366 9565

Playback PIN code: 7321731#

 

 

 

AER - actual exchange rates; CER - constant 2013 exchange rates

 

1ongoing revenue represents revenue with disposals removed and includes revenue from acquisitions.

2 before amortisation and impairment of intangibles (excluding computer software), reorganisation costs and one-off items, and net interest credit from pensions

 

This announcement contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUNRWRSBAARAA
Date   Source Headline
31st Mar 20211:16 pmRNSTotal Voting Rights
31st Mar 202110:33 amRNSAnnual Financial Report
30th Mar 20216:23 pmRNSDirector Declaration
24th Mar 20215:55 pmRNSDirector/PDMR Shareholding
12th Mar 20219:00 amRNSAdditional Listing
4th Mar 20217:05 amRNSDirectorate Change
4th Mar 20217:00 amRNSFinal Results
17th Feb 20215:45 pmRNSDirector Declaration
8th Jan 20217:00 amRNSQ4 2020 Acquisitions and Trading Update
27th Nov 20202:25 pmBUSEarly Repurchase(s)
27th Nov 20202:22 pmBUSEarly Repurchase(s)
24th Nov 20205:25 pmRNSDirector/PDMR Shareholding
20th Nov 20207:00 amRNSResult of Tender Offer for Notes due 2021
12th Nov 20209:02 amRNSTender Offer for Notes due 2021
22nd Oct 20207:00 amRNSQ3 Trading Update
8th Oct 20207:00 amRNSSuccessful EUR600m 8-year bond transaction priced
1st Oct 20209:00 amRNSBlock listing Interim Review
28th Aug 20203:40 pmRNSDirector/PDMR Shareholding
7th Aug 20205:24 pmRNSDirector/PDMR Shareholding
30th Jul 20207:00 amRNSInterim Results
6th Jul 20207:00 amRNSDirectorate Change
21st May 202011:00 amRNSDirector/PDMR Shareholding
13th May 20205:15 pmRNSResult of AGM
7th May 20204:45 pmRNSDirector/PDMR Shareholding
27th Apr 20203:50 pmRNSDisclosure of Rights Attached to Equity Shares
17th Apr 202011:59 amRNSDirector/PDMR Shareholding
16th Apr 20207:00 amRNSQ1 Trading Update
14th Apr 20205:26 pmRNSHolding(s) in Company
9th Apr 20204:35 pmRNSDirector/PDMR Shareholding
2nd Apr 20201:36 pmRNSDirector/PDMR Shareholding
1st Apr 20205:33 pmRNSConfirmation of Non-Executive Director Appointment
1st Apr 20209:24 amRNSBlock listing Interim Review
31st Mar 20202:18 pmRNSTotal Voting Rights
30th Mar 202012:37 pmRNSRedemption of 4.5% debenture stock
30th Mar 202012:24 pmRNSRedemption of 5% debenture stock
27th Mar 202011:00 amRNSHolding(s) in Company
26th Mar 20204:41 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
26th Mar 202011:29 amRNSAnnual Financial Report
25th Mar 20207:00 amRNSTrading Update
19th Mar 202011:30 amRNSDirector Declaration
17th Mar 20201:15 pmRNSAdditional Listing
6th Mar 202012:00 pmRNSHolding(s) in Company
27th Feb 20207:05 amRNSDirectorate Change
27th Feb 20207:00 amRNSFinal Results
21st Feb 20204:00 pmRNSHolding(s) in Company
24th Dec 20191:10 pmRNSHolding(s) in Company
19th Dec 20192:40 pmRNSDirector/PDMR Shareholding
17th Dec 20195:10 pmRNSHolding(s) in Company
26th Nov 20196:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.